Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.31 |
| ▸ | PYGL | P06737 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15373033 | 1.00 | HPGDS (0.35) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL10177451 | 0.88 | HPGDS (0.38) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL882760 | 0.87 | MAPK13 (0.41) | HPGDSSCN10AMAPK13MAPK12MAPK11 | |
| SCHEMBL933682 | 0.84 | HPGDS (0.37) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL16572630 | 0.83 | SCN10A (0.51) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL10144768 | 0.83 | SCN10A (0.51) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL16405116 | 0.83 | SCN10A (0.51) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9980576 | 0.83 | MAPK13 (0.41) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL10236922 | 0.81 | SCN10A (0.38) | SCN10AMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1359964 | 0.81 | MAPK13 (0.40) | HPGDSSCN10AMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885SCN10A 3547/4885NR1H4 333/4885 |
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885SCN10A 3547/4885NR1H4 333/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | HPGDS 2085/4885SCN10A 3547/4885NR1H4 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.